Granulocyte colony-stimulating factor for chemotherapy-induced neutropenia in patients with small cell lung cancer View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2005-08

AUTHORS

Elizabeth A. Calhoun, Glen T. Schumock, June M. McKoy, Simon Pickard, Karen A. Fitzner, Elizabeth A. Heckinger, Eowyn F. Powell, Kathyrn R. McCaffrey, Charles L. Bennett

ABSTRACT

Recombinant granulocyte colony-stimulating factor (G-CSF) [filgrastim and lenograstim] and pegylated G-CSF (pegfilgrastim) have been shown to reduce the severity and duration of chemotherapy-associated febrile neutropenia (FN) when administered prophylactically to cancer patients receiving chemotherapeutic regimens. The American Society of Clinical Oncology (ASCO) evidence-based clinical guidelines published in 1994, 1996 and 1997 recommended primary prophylaxis with G-CSF for cancer patients. The 2000 ASCO update, with the same recommendation, highlights the importance of economic considerations in decision making for CSFs. This paper reviews the available cost-effectiveness evidence on the use of G-CSF as primary prophylaxis against FN in patients with small cell lung cancer (SCLC).Cost-effectiveness ratios from a healthcare payer perspective supported the use of filgrastim as primary prophylaxis for people with SCLC, on the basis of both clinical and economic benefits, treated with chemotherapeutic regimens that have an FN rate in the range of 40–60%. However, when indirect and patient out-of-pocket costs attributable to severe FN are included, available evidence suggests that the risk threshold may be reduced by more than half.Given that FN rates associated with chemotherapeutic regimens for SCLC are generally <40%, then few circumstances would warrant the use of G-CSFs (filgrastim and lenograstim) under the current rule. However, inclusion of indirect costs would lower the cost-effectiveness threshold. Future cost-effectiveness studies of medications such as pegfilgrastim should attempt to capture the societal perspective by incorporating productivity-related costs and using base-case rates of FN reported in the literature. More... »

PAGES

767-775

Identifiers

URI

http://scigraph.springernature.com/pub.10.2165/00019053-200523080-00003

DOI

http://dx.doi.org/10.2165/00019053-200523080-00003

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1038420911

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/16097839


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Attention Deficit Disorder with Hyperactivity", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Small Cell", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chicago", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Costs and Cost Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "England", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Granulocyte Colony-Stimulating Factor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lung Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Midwestern United States", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neutropenia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quality of Life", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Recombinant Proteins", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Health Policy and Administration, University of Illinois at Chicago, Chicago, Illinois, USA", 
          "id": "http://www.grid.ac/institutes/grid.185648.6", 
          "name": [
            "Department of Health Policy and Administration, University of Illinois at Chicago, Chicago, Illinois, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Calhoun", 
        "givenName": "Elizabeth A.", 
        "id": "sg:person.016654752007.02", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016654752007.02"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The Center for Pharmacoeconomic Research, University of Illinois at Chicago, Chicago, Illinois, USA", 
          "id": "http://www.grid.ac/institutes/grid.185648.6", 
          "name": [
            "The Center for Pharmacoeconomic Research, University of Illinois at Chicago, Chicago, Illinois, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schumock", 
        "givenName": "Glen T.", 
        "id": "sg:person.01331114412.87", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01331114412.87"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Northwestern University Medical School, Chicago, Illinois, USA", 
          "id": "http://www.grid.ac/institutes/grid.16753.36", 
          "name": [
            "Department of Medicine, Northwestern University Medical School, Chicago, Illinois, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "McKoy", 
        "givenName": "June M.", 
        "id": "sg:person.01330740160.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01330740160.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The Center for Pharmacoeconomic Research, University of Illinois at Chicago, Chicago, Illinois, USA", 
          "id": "http://www.grid.ac/institutes/grid.185648.6", 
          "name": [
            "The Center for Pharmacoeconomic Research, University of Illinois at Chicago, Chicago, Illinois, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pickard", 
        "givenName": "Simon", 
        "id": "sg:person.01152461067.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01152461067.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Northwestern University Medical School, Chicago, Illinois, USA", 
          "id": "http://www.grid.ac/institutes/grid.16753.36", 
          "name": [
            "Department of Medicine, Northwestern University Medical School, Chicago, Illinois, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fitzner", 
        "givenName": "Karen A.", 
        "id": "sg:person.01220574267.85", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01220574267.85"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Northwestern University Medical School, Chicago, Illinois, USA", 
          "id": "http://www.grid.ac/institutes/grid.16753.36", 
          "name": [
            "Department of Medicine, Northwestern University Medical School, Chicago, Illinois, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Heckinger", 
        "givenName": "Elizabeth A.", 
        "id": "sg:person.0615632750.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0615632750.10"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Northwestern University Medical School, Chicago, Illinois, USA", 
          "id": "http://www.grid.ac/institutes/grid.16753.36", 
          "name": [
            "Department of Medicine, Northwestern University Medical School, Chicago, Illinois, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Powell", 
        "givenName": "Eowyn F.", 
        "id": "sg:person.01335022667.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01335022667.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Northwestern University Medical School, Chicago, Illinois, USA", 
          "id": "http://www.grid.ac/institutes/grid.16753.36", 
          "name": [
            "Department of Medicine, Northwestern University Medical School, Chicago, Illinois, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "McCaffrey", 
        "givenName": "Kathyrn R.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Northwestern University Medical School, Chicago, Illinois, USA", 
          "id": "http://www.grid.ac/institutes/grid.16753.36", 
          "name": [
            "Department of Medicine, Northwestern University Medical School, Chicago, Illinois, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bennett", 
        "givenName": "Charles L.", 
        "id": "sg:person.01100705232.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01100705232.37"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.2165/00019053-199400062-00008", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019047021", 
          "https://doi.org/10.2165/00019053-199400062-00008"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2005-08", 
    "datePublishedReg": "2005-08-01", 
    "description": "Recombinant granulocyte colony-stimulating factor (G-CSF) [filgrastim and lenograstim] and pegylated G-CSF (pegfilgrastim) have been shown to reduce the severity and duration of chemotherapy-associated febrile neutropenia (FN) when administered prophylactically to cancer patients receiving chemotherapeutic regimens. The American Society of Clinical Oncology (ASCO) evidence-based clinical guidelines published in 1994, 1996 and 1997 recommended primary prophylaxis with G-CSF for cancer patients. The 2000 ASCO update, with the same recommendation, highlights the importance of economic considerations in decision making for CSFs. This paper reviews the available cost-effectiveness evidence on the use of G-CSF as primary prophylaxis against FN in patients with small cell lung cancer (SCLC).Cost-effectiveness ratios from a healthcare payer perspective supported the use of filgrastim as primary prophylaxis for people with SCLC, on the basis of both clinical and economic benefits, treated with chemotherapeutic regimens that have an FN rate in the range of 40\u201360%. However, when indirect and patient out-of-pocket costs attributable to severe FN are included, available evidence suggests that the risk threshold may be reduced by more than half.Given that FN rates associated with chemotherapeutic regimens for SCLC are generally <40%, then few circumstances would warrant the use of G-CSFs (filgrastim and lenograstim) under the current rule. However, inclusion of indirect costs would lower the cost-effectiveness threshold. Future cost-effectiveness studies of medications such as pegfilgrastim should attempt to capture the societal perspective by incorporating productivity-related costs and using base-case rates of FN reported in the literature.", 
    "genre": "article", 
    "id": "sg:pub.10.2165/00019053-200523080-00003", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1102812", 
        "issn": [
          "1170-7690", 
          "1179-2027"
        ], 
        "name": "PharmacoEconomics", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "8", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "23"
      }
    ], 
    "keywords": [
      "small cell lung cancer", 
      "febrile neutropenia", 
      "cell lung cancer", 
      "granulocyte colony-stimulating factor", 
      "primary prophylaxis", 
      "chemotherapeutic regimens", 
      "colony-stimulating factor", 
      "cancer patients", 
      "lung cancer", 
      "chemotherapy-associated febrile neutropenia", 
      "evidence-based clinical guidelines", 
      "FN rate", 
      "recombinant granulocyte colony-stimulating factor", 
      "use of filgrastim", 
      "severe febrile neutropenia", 
      "future cost-effectiveness studies", 
      "chemotherapy-induced neutropenia", 
      "healthcare payer perspective", 
      "productivity-related costs", 
      "cost-effectiveness ratio", 
      "cost-effectiveness evidence", 
      "cost-effectiveness studies", 
      "cost-effectiveness threshold", 
      "clinical guidelines", 
      "payer perspective", 
      "patients", 
      "prophylaxis", 
      "pocket costs", 
      "regimens", 
      "societal perspective", 
      "base case rate", 
      "available evidence", 
      "CSF", 
      "indirect costs", 
      "neutropenia", 
      "American Society", 
      "risk threshold", 
      "cancer", 
      "same recommendations", 
      "pegfilgrastim", 
      "medications", 
      "filgrastim", 
      "ASCO", 
      "severity", 
      "evidence", 
      "rate", 
      "factors", 
      "duration", 
      "CSFs", 
      "use", 
      "guidelines", 
      "threshold", 
      "recommendations", 
      "half", 
      "study", 
      "benefits", 
      "people", 
      "literature", 
      "inclusion", 
      "ratio", 
      "importance", 
      "cost", 
      "circumstances", 
      "economic considerations", 
      "perspective", 
      "decisions", 
      "basis", 
      "consideration", 
      "society", 
      "current rules", 
      "range", 
      "economic benefits", 
      "rules", 
      "paper"
    ], 
    "name": "Granulocyte colony-stimulating factor for chemotherapy-induced neutropenia in patients with small cell lung cancer", 
    "pagination": "767-775", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1038420911"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.2165/00019053-200523080-00003"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "16097839"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.2165/00019053-200523080-00003", 
      "https://app.dimensions.ai/details/publication/pub.1038420911"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-05-20T07:23", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/article/article_398.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.2165/00019053-200523080-00003"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.2165/00019053-200523080-00003'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.2165/00019053-200523080-00003'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.2165/00019053-200523080-00003'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.2165/00019053-200523080-00003'


 

This table displays all metadata directly associated to this object as RDF triples.

256 TRIPLES      22 PREDICATES      116 URIs      106 LITERALS      20 BLANK NODES

Subject Predicate Object
1 sg:pub.10.2165/00019053-200523080-00003 schema:about N1ec823a9c79f4ea6b652a153cba90040
2 N3381312412f745d7b0d1ebc3c408bf3f
3 N393706f8822b41f8b46cdcf09c94e00c
4 N41be6b3cb17f4133b66d9170cbb7dc0b
5 N45a4206618724dc0beaf66856652d2f5
6 N6af3610009244233b9643d80590991ee
7 N8179d44751494b84be577199d1a5f454
8 N8fe505c44a5f44219d624b576a74d42f
9 Na9ebf440b3c24b109841d4b49f0d5b80
10 Nad3f3934580e47818e9eac16791caf11
11 Naf58bf4249a7499a86236e0b315ae05c
12 Nba4872181ccd4844aa51836403951fac
13 Nc54482de44894174a0efb24268a99831
14 anzsrc-for:11
15 anzsrc-for:1112
16 anzsrc-for:1117
17 schema:author N83b5c88cfa03465fad35762fcbf1dd5a
18 schema:citation sg:pub.10.2165/00019053-199400062-00008
19 schema:datePublished 2005-08
20 schema:datePublishedReg 2005-08-01
21 schema:description Recombinant granulocyte colony-stimulating factor (G-CSF) [filgrastim and lenograstim] and pegylated G-CSF (pegfilgrastim) have been shown to reduce the severity and duration of chemotherapy-associated febrile neutropenia (FN) when administered prophylactically to cancer patients receiving chemotherapeutic regimens. The American Society of Clinical Oncology (ASCO) evidence-based clinical guidelines published in 1994, 1996 and 1997 recommended primary prophylaxis with G-CSF for cancer patients. The 2000 ASCO update, with the same recommendation, highlights the importance of economic considerations in decision making for CSFs. This paper reviews the available cost-effectiveness evidence on the use of G-CSF as primary prophylaxis against FN in patients with small cell lung cancer (SCLC).Cost-effectiveness ratios from a healthcare payer perspective supported the use of filgrastim as primary prophylaxis for people with SCLC, on the basis of both clinical and economic benefits, treated with chemotherapeutic regimens that have an FN rate in the range of 40–60%. However, when indirect and patient out-of-pocket costs attributable to severe FN are included, available evidence suggests that the risk threshold may be reduced by more than half.Given that FN rates associated with chemotherapeutic regimens for SCLC are generally <40%, then few circumstances would warrant the use of G-CSFs (filgrastim and lenograstim) under the current rule. However, inclusion of indirect costs would lower the cost-effectiveness threshold. Future cost-effectiveness studies of medications such as pegfilgrastim should attempt to capture the societal perspective by incorporating productivity-related costs and using base-case rates of FN reported in the literature.
22 schema:genre article
23 schema:inLanguage en
24 schema:isAccessibleForFree false
25 schema:isPartOf N16879067dce34b24be6ef785e3c204bb
26 N63eea45f3ee9464bbc7f3a5072a5b261
27 sg:journal.1102812
28 schema:keywords ASCO
29 American Society
30 CSF
31 CSFs
32 FN rate
33 available evidence
34 base case rate
35 basis
36 benefits
37 cancer
38 cancer patients
39 cell lung cancer
40 chemotherapeutic regimens
41 chemotherapy-associated febrile neutropenia
42 chemotherapy-induced neutropenia
43 circumstances
44 clinical guidelines
45 colony-stimulating factor
46 consideration
47 cost
48 cost-effectiveness evidence
49 cost-effectiveness ratio
50 cost-effectiveness studies
51 cost-effectiveness threshold
52 current rules
53 decisions
54 duration
55 economic benefits
56 economic considerations
57 evidence
58 evidence-based clinical guidelines
59 factors
60 febrile neutropenia
61 filgrastim
62 future cost-effectiveness studies
63 granulocyte colony-stimulating factor
64 guidelines
65 half
66 healthcare payer perspective
67 importance
68 inclusion
69 indirect costs
70 literature
71 lung cancer
72 medications
73 neutropenia
74 paper
75 patients
76 payer perspective
77 pegfilgrastim
78 people
79 perspective
80 pocket costs
81 primary prophylaxis
82 productivity-related costs
83 prophylaxis
84 range
85 rate
86 ratio
87 recombinant granulocyte colony-stimulating factor
88 recommendations
89 regimens
90 risk threshold
91 rules
92 same recommendations
93 severe febrile neutropenia
94 severity
95 small cell lung cancer
96 societal perspective
97 society
98 study
99 threshold
100 use
101 use of filgrastim
102 schema:name Granulocyte colony-stimulating factor for chemotherapy-induced neutropenia in patients with small cell lung cancer
103 schema:pagination 767-775
104 schema:productId N038f133ca12943c39ed67cd0078b0efb
105 N047dc6b285ca48fd85abbdd430d0c544
106 Nf43d5c654a264992ab5c75ce787e010e
107 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038420911
108 https://doi.org/10.2165/00019053-200523080-00003
109 schema:sdDatePublished 2022-05-20T07:23
110 schema:sdLicense https://scigraph.springernature.com/explorer/license/
111 schema:sdPublisher N26368eea2c0e4adca5169934244cbd4b
112 schema:url https://doi.org/10.2165/00019053-200523080-00003
113 sgo:license sg:explorer/license/
114 sgo:sdDataset articles
115 rdf:type schema:ScholarlyArticle
116 N038f133ca12943c39ed67cd0078b0efb schema:name pubmed_id
117 schema:value 16097839
118 rdf:type schema:PropertyValue
119 N047dc6b285ca48fd85abbdd430d0c544 schema:name doi
120 schema:value 10.2165/00019053-200523080-00003
121 rdf:type schema:PropertyValue
122 N06e83733b1c244b9a6915ff2ed21d2ba rdf:first sg:person.01100705232.37
123 rdf:rest rdf:nil
124 N16879067dce34b24be6ef785e3c204bb schema:volumeNumber 23
125 rdf:type schema:PublicationVolume
126 N1ec823a9c79f4ea6b652a153cba90040 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Costs and Cost Analysis
128 rdf:type schema:DefinedTerm
129 N26368eea2c0e4adca5169934244cbd4b schema:name Springer Nature - SN SciGraph project
130 rdf:type schema:Organization
131 N2d3c5cf60776418485e0b9d5d9b1a22f rdf:first sg:person.0615632750.10
132 rdf:rest Nd2f6e2528b864a3585c655323e3d088b
133 N3381312412f745d7b0d1ebc3c408bf3f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Recombinant Proteins
135 rdf:type schema:DefinedTerm
136 N393706f8822b41f8b46cdcf09c94e00c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Attention Deficit Disorder with Hyperactivity
138 rdf:type schema:DefinedTerm
139 N3b3970bcd2c54812a2cad787a0be247c rdf:first sg:person.01331114412.87
140 rdf:rest Ne572b8e30dfb4d6fbbb13a44d80edb73
141 N41be6b3cb17f4133b66d9170cbb7dc0b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Granulocyte Colony-Stimulating Factor
143 rdf:type schema:DefinedTerm
144 N45a4206618724dc0beaf66856652d2f5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Chicago
146 rdf:type schema:DefinedTerm
147 N55d795de25824e1299f72f382f07f4fa schema:affiliation grid-institutes:grid.16753.36
148 schema:familyName McCaffrey
149 schema:givenName Kathyrn R.
150 rdf:type schema:Person
151 N63eea45f3ee9464bbc7f3a5072a5b261 schema:issueNumber 8
152 rdf:type schema:PublicationIssue
153 N6af3610009244233b9643d80590991ee schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Humans
155 rdf:type schema:DefinedTerm
156 N8179d44751494b84be577199d1a5f454 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Antineoplastic Agents
158 rdf:type schema:DefinedTerm
159 N83b5c88cfa03465fad35762fcbf1dd5a rdf:first sg:person.016654752007.02
160 rdf:rest N3b3970bcd2c54812a2cad787a0be247c
161 N8fe505c44a5f44219d624b576a74d42f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name England
163 rdf:type schema:DefinedTerm
164 Na0681550e671481d969802e507430264 rdf:first N55d795de25824e1299f72f382f07f4fa
165 rdf:rest N06e83733b1c244b9a6915ff2ed21d2ba
166 Na9ebf440b3c24b109841d4b49f0d5b80 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Quality of Life
168 rdf:type schema:DefinedTerm
169 Nad3f3934580e47818e9eac16791caf11 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Carcinoma, Small Cell
171 rdf:type schema:DefinedTerm
172 Naf58bf4249a7499a86236e0b315ae05c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Midwestern United States
174 rdf:type schema:DefinedTerm
175 Nba4872181ccd4844aa51836403951fac schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Neutropenia
177 rdf:type schema:DefinedTerm
178 Nc54482de44894174a0efb24268a99831 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Lung Neoplasms
180 rdf:type schema:DefinedTerm
181 Nd2f6e2528b864a3585c655323e3d088b rdf:first sg:person.01335022667.49
182 rdf:rest Na0681550e671481d969802e507430264
183 Ne0e2cd368e154b6d9fda5536e7841ae7 rdf:first sg:person.01152461067.24
184 rdf:rest Ne6edd518f3f34163a989e94a7740e87b
185 Ne572b8e30dfb4d6fbbb13a44d80edb73 rdf:first sg:person.01330740160.15
186 rdf:rest Ne0e2cd368e154b6d9fda5536e7841ae7
187 Ne6edd518f3f34163a989e94a7740e87b rdf:first sg:person.01220574267.85
188 rdf:rest N2d3c5cf60776418485e0b9d5d9b1a22f
189 Nf43d5c654a264992ab5c75ce787e010e schema:name dimensions_id
190 schema:value pub.1038420911
191 rdf:type schema:PropertyValue
192 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
193 schema:name Medical and Health Sciences
194 rdf:type schema:DefinedTerm
195 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
196 schema:name Oncology and Carcinogenesis
197 rdf:type schema:DefinedTerm
198 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
199 schema:name Public Health and Health Services
200 rdf:type schema:DefinedTerm
201 sg:journal.1102812 schema:issn 1170-7690
202 1179-2027
203 schema:name PharmacoEconomics
204 schema:publisher Springer Nature
205 rdf:type schema:Periodical
206 sg:person.01100705232.37 schema:affiliation grid-institutes:grid.16753.36
207 schema:familyName Bennett
208 schema:givenName Charles L.
209 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01100705232.37
210 rdf:type schema:Person
211 sg:person.01152461067.24 schema:affiliation grid-institutes:grid.185648.6
212 schema:familyName Pickard
213 schema:givenName Simon
214 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01152461067.24
215 rdf:type schema:Person
216 sg:person.01220574267.85 schema:affiliation grid-institutes:grid.16753.36
217 schema:familyName Fitzner
218 schema:givenName Karen A.
219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01220574267.85
220 rdf:type schema:Person
221 sg:person.01330740160.15 schema:affiliation grid-institutes:grid.16753.36
222 schema:familyName McKoy
223 schema:givenName June M.
224 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01330740160.15
225 rdf:type schema:Person
226 sg:person.01331114412.87 schema:affiliation grid-institutes:grid.185648.6
227 schema:familyName Schumock
228 schema:givenName Glen T.
229 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01331114412.87
230 rdf:type schema:Person
231 sg:person.01335022667.49 schema:affiliation grid-institutes:grid.16753.36
232 schema:familyName Powell
233 schema:givenName Eowyn F.
234 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01335022667.49
235 rdf:type schema:Person
236 sg:person.016654752007.02 schema:affiliation grid-institutes:grid.185648.6
237 schema:familyName Calhoun
238 schema:givenName Elizabeth A.
239 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016654752007.02
240 rdf:type schema:Person
241 sg:person.0615632750.10 schema:affiliation grid-institutes:grid.16753.36
242 schema:familyName Heckinger
243 schema:givenName Elizabeth A.
244 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0615632750.10
245 rdf:type schema:Person
246 sg:pub.10.2165/00019053-199400062-00008 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019047021
247 https://doi.org/10.2165/00019053-199400062-00008
248 rdf:type schema:CreativeWork
249 grid-institutes:grid.16753.36 schema:alternateName Department of Medicine, Northwestern University Medical School, Chicago, Illinois, USA
250 schema:name Department of Medicine, Northwestern University Medical School, Chicago, Illinois, USA
251 rdf:type schema:Organization
252 grid-institutes:grid.185648.6 schema:alternateName Department of Health Policy and Administration, University of Illinois at Chicago, Chicago, Illinois, USA
253 The Center for Pharmacoeconomic Research, University of Illinois at Chicago, Chicago, Illinois, USA
254 schema:name Department of Health Policy and Administration, University of Illinois at Chicago, Chicago, Illinois, USA
255 The Center for Pharmacoeconomic Research, University of Illinois at Chicago, Chicago, Illinois, USA
256 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...